In an interview with PharmaShots, Dr. Andreas Harstrick, Chief Medical Officer at Affimed shared his views on updated clinical data related to their lead innate cell engager AFM13 at the virtual 62nd American Society of Hematology (ASH) annual meeting. Shots: The study showed an ORR of 42% (6/14 patients) and demonstrated clinical activity in two […]Read More
